These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12841534)

  • 1. Prevention of type 1 diabetes: where do we start?
    Pozzilli P; Adorini L
    J Endocrinol Invest; 2003 Apr; 26(4):292-3. PubMed ID: 12841534
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical studies. Trying to reset the clock on type 1 diabetes.
    Couzin-Frankel J
    Science; 2011 Aug; 333(6044):819-21. PubMed ID: 21835995
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapies in diabetes mellitus type 1.
    Gupta S
    Med Clin North Am; 2012 May; 96(3):621-34, xi. PubMed ID: 22703858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we change the course of beta-cell destruction in type 1 diabetes?
    Gale EA
    N Engl J Med; 2002 May; 346(22):1740-2. PubMed ID: 12037155
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of type 1 diabetes: what next?
    Dunger DB; Todd JA
    Lancet; 2008 Nov; 372(9651):1710-1. PubMed ID: 18814907
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Type 1 diabetes: getting beyond a negative first impression.
    Pozzilli P; Strollo R
    Immunotherapy; 2012 Jul; 4(7):655-8. PubMed ID: 22853748
    [No Abstract]   [Full Text] [Related]  

  • 8. Preventing type 1 diabetes may someday become possible.
    Vastag B
    JAMA; 2002 Feb; 287(6):701-2. PubMed ID: 11851514
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
    Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
    Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
    Sherry NA; Chen W; Kushner JA; Glandt M; Tang Q; Tsai S; Santamaria P; Bluestone JA; Brillantes AM; Herold KC
    Endocrinology; 2007 Nov; 148(11):5136-44. PubMed ID: 17673522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes.
    Kägi D; Ho A; Odermatt B; Zakarian A; Ohashi PS; Mak TW
    J Immunol; 1999 Apr; 162(8):4598-605. PubMed ID: 10201999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].
    Chatenoud L
    Med Sci (Paris); 2006 Jan; 22(1):5-6. PubMed ID: 16386207
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of diabetes mellitus with biologic therapeutics].
    Larsen CM; Mandrup-Poulsen T
    Ugeskr Laeger; 2008 Jun; 170(24):2134-7. PubMed ID: 18565296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Otelixizumab in the treatment of type 1 diabetes mellitus.
    Sprangers B; Van der Schueren B; Gillard P; Mathieu C
    Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release.
    Vossen AC; Tibbe GJ; Buurman WA; Benner R; Savelkoul HF
    Eur Cytokine Netw; 1996 Dec; 7(4):751-5. PubMed ID: 9010677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD3-specific antibody-induced T-cell apoptosis and apoptotic cell uptake lead to CD3-specific antibody-induced tolerance].
    Perruche S; Saas P
    Med Sci (Paris); 2009 Apr; 25(4):325-7. PubMed ID: 19409176
    [No Abstract]   [Full Text] [Related]  

  • 17. [Type 1 diabetes mellitus. Early detection and prevention].
    Hummel M; Achenbach P
    Internist (Berl); 2015 May; 56(5):475-83. PubMed ID: 25894242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
    Chatenoud L
    Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes.
    Cannons JL; Chamberlain G; Howson J; Smink LJ; Todd JA; Peterson LB; Wicker LS; Watts TH
    J Autoimmun; 2005 Aug; 25(1):13-20. PubMed ID: 15998581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation.
    Bachmann F; Buechner SA; Wernli M; Strebel S; Erb P
    J Invest Dermatol; 2001 Jul; 117(1):59-66. PubMed ID: 11442750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.